Related by context. All words. (Click for frequent words.) 72 neoadjuvant chemotherapy 71 brain metastases 71 lung metastases 71 metastases 71 micrometastases 71 tumor recurrence 70 lymph node metastases 70 renal tumors 70 metastatic lesions 70 metastatic RCC 70 metastatic disease 70 metastatic tumors 69 neoadjuvant therapy 69 basal cell carcinoma BCC 69 IV NSCLC 69 distant metastases 69 peritoneal carcinomatosis 69 epithelial tumors 68 lung metastasis 68 adjuvant radiation 68 stage IIIB 68 carcinoid 68 pancreatic adenocarcinoma 68 radical nephrectomy 68 cytoreduction 67 distant metastasis 67 curative resection 67 resectable 67 preoperative chemotherapy 67 GISTs 67 adenocarcinomas 67 locoregional recurrence 67 recurrent NSCLC 67 colorectal liver metastases 67 CMV disease 67 metastatic lung cancer 67 unresectable 67 neuroendocrine tumors 67 contralateral breast 67 nonsmall cell lung cancer 67 chemoradiotherapy 67 NSCLC 66 lung tumors 66 pulmonary metastases 66 metastatic renal cell carcinoma 66 advanced adenomas 66 cytoreductive surgery 66 Hepatocellular Carcinoma HCC 66 adenoma 66 hepatic metastases 66 tumor shrinkage 66 hepatocellular carcinoma HCC 66 resected 66 carcinoid tumors 66 chemoradiation 66 PCa 66 renal cell carcinomas 65 breast carcinoma 65 superficial bladder cancer 65 SCCHN 65 thymoma 65 breast carcinomas 65 adjuvant radiotherapy 65 hepatectomy 65 nephrectomy 65 metastatic prostate cancer 65 colorectal carcinoma 65 recurrent glioblastoma multiforme 65 metachronous 65 liver metastasis 65 precursor lesions 65 cystectomy 65 hepatocellular carcinoma 65 Tavocept 65 gastrointestinal stromal tumors 65 lymphadenectomy 65 tumor resection 65 liver resection 65 BRAF mutation 65 receptor tyrosine kinase inhibitor 65 axillary nodes 65 ALND 65 leukemia AML 65 TACE 65 locoregional 65 concurrent chemoradiation 65 pCR 65 malignant pleural mesothelioma 65 gastric adenocarcinoma 64 neoadjuvant 64 KRAS mutations occur 64 EUS FNA 64 EGFR mutations 64 metastatic neuroendocrine tumors 64 metastatic cancers 64 locoregional disease 64 vandetanib 64 tumors 64 advanced adenoma 64 debulking surgery 64 fallopian tube carcinoma 64 recurrent GBM 64 hepatocellular cancer 64 mg kg dose 64 carcinoids 64 HNSCC 64 adjuvant therapy 64 metastatic gastric 64 axillary lymph nodes 64 Amrubicin 64 HER2 positive metastatic breast 64 neoplasms 64 prostate cancer CaP 64 NMIBC 64 EBRT 64 bone metastasis 64 adenomatous 64 INCB# [003] 64 KRAS wild 64 ovarian carcinoma 64 nodal metastasis 64 R0 resection 64 WT1 63 HER2 positive tumors 63 intestinal metaplasia 63 colorectal cancer liver metastases 63 IV melanoma 63 PAOD 63 tumor regression 63 histologies 63 HGS ETR1 63 mRCC 63 biochemical relapse 63 biliary tract cancer 63 androgen deprivation 63 evaluable patients 63 carcinoma 63 K ras mutations 63 IMGN# 63 Surgical resection 63 systemic ALCL 63 malignancies 63 p#HER# 63 nonmetastatic 63 heavily pretreated 63 allogeneic stem cell 63 sentinel lymph node biopsy 63 heavily pretreated patients 63 breast cancer subtypes 63 non squamous NSCLC 63 chemoresistant 63 histologically confirmed 63 stage IIIB IV 63 GIST tumors 63 pancreatic neuroendocrine tumors 63 squamous histology 63 axitinib 63 dose cohorts 63 pancreatic carcinoma 63 renal cell carcinoma 63 axillary dissection 63 taxane chemotherapy 63 MAGE A3 63 EGFR mutation 63 metastatic melanomas 63 glioblastoma tumors 63 colorectal tumors 63 differentiated thyroid 63 underwent resection 63 urothelial carcinoma 63 olaparib 63 solid tumors 63 lymph node involvement 63 bortezomib 63 NSCLC tumors 63 dose cohort 63 peritoneal cancer 63 HER2 positive 63 bladder cancers 63 chemoembolization 63 ErbB2 positive 63 metastatic pancreatic 63 squamous cell carcinoma SCC 63 prostate cancer CRPC 63 neuroendocrine cancers 63 castration resistant prostate cancer 63 recurrent metastatic 63 oblimersen 63 depsipeptide 63 gastrointestinal stromal tumor GIST 63 Doxil ® 63 recurrent glioblastoma 63 tumor xenograft models 63 ADPKD 63 EGFR inhibitors 62 colorectal adenocarcinoma 62 mCRC patients 62 gefitinib 62 HBeAg negative 62 hepatoma 62 relapsed SCLC 62 graft dysfunction 62 NOD SCID mice 62 chemoradiation therapy 62 complete cytogenetic response 62 unresectable tumors 62 metastatic cancer 62 operable breast cancer 62 atherosclerotic lesions 62 medullary thyroid cancer 62 skeletal metastases 62 PSADT 62 histologically 62 adjuvant chemotherapy 62 neuroblastoma tumors 62 platinum refractory 62 nonmelanoma skin cancers 62 postoperative chemotherapy 62 complete remissions 62 gastric cancers 62 prostate carcinoma 62 revascularization procedures 62 Bezielle 62 HER2 overexpression 62 hepatocellular carcinomas 62 cervical lymph nodes 62 medically inoperable 62 neoadjuvant treatment 62 surgical debulking 62 neoplastic cells 62 evaluable 62 FOLFOX4 62 melanoma tumors 62 SLNB 62 malignant lesions 62 advanced NSCLC 62 colorectal polyp 62 neoplasm 62 EGF receptor 62 papillary renal cell carcinoma 62 GBM tumors 62 metastatic bladder 62 prior chemotherapy regimens 62 fallopian tube cancers 62 mucinous 62 cytologically confirmed 62 sarcomas 62 MGUS 62 cilengitide 62 taxane therapy 62 pT2 62 KRAS mutation 62 endometrial cancers 62 stage IIIb IV 62 thoracoscopic lobectomy 62 standard chemotherapy regimens 62 dosing cohort 62 cystic lesions 62 CMV infection 62 EGFRvIII 62 endostatin 62 gastrointestinal stromal tumors GIST 62 IGF 1R 62 basal cell carcinomas 62 lymph node dissection 62 paroxysmal AF 62 nonresponders 62 adecatumumab 62 metastatic HRPC 62 occult metastases 62 pancreatic cancers 62 HGPIN 62 MALT lymphoma 62 metastatic melanoma 62 dacarbazine DTIC 62 OPAXIO 62 CEQ# 62 metastatic 62 disease progression 62 invasive carcinoma 62 micrometastasis 62 imetelstat 62 resected pancreatic cancer 62 sorafenib Nexavar 62 unresectable stage 62 biochemical recurrence 62 leiomyosarcoma 62 intestinal polyps 62 sentinel lymph nodes 62 ximelagatran 62 prostate adenocarcinoma 61 cervical carcinoma 61 radiation sensitizer 61 stage IIIA 61 lobular carcinoma 61 pancreatic NET 61 osteosarcomas 61 lymphatic tissue 61 orthotopic 61 carcinoid tumor 61 extrapleural pneumonectomy 61 underwent surgical resection 61 lymphocytosis 61 histologically proven 61 axillary node dissection 61 pheochromocytoma 61 metastatic liver 61 PSMA ADC 61 GVAX 61 GPNMB 61 serous ovarian cancer 61 mapatumumab 61 refractory AML 61 EGFr 61 BCR ABL mutations 61 posaconazole 61 Adjuvant chemotherapy 61 MGd 61 adrenalectomy 61 CYT# potent vascular disrupting 61 pneumonectomy 61 metastatic malignant melanoma 61 recurrent VTE 61 phase IIb clinical 61 xenograft models 61 cell lymphoma CTCL 61 gemcitabine chemotherapy 61 mTOR inhibitors 61 Gleevec resistant 61 tumoral 61 BRCA deficient 61 metastatic colorectal 61 forodesine 61 seminoma 61 invasive ductal 61 axillary lymph node dissection 61 HER2 negative 61 gemcitabine carboplatin 61 adenocarcinoma 61 5FU 61 breast tumors 61 soft tissue sarcomas 61 pre malignant lesions 61 sarcomatoid 61 hypercalcemia 61 lung adenocarcinomas 61 tumor 61 prospectively defined 61 tumorigenicity 61 mammary tumors 61 bleomycin 61 imatinib therapy 61 cancer mCRC 61 squamous 61 chemotherapeutic regimens 61 mesotheliomas 61 prostate cancer metastases 61 premalignant lesions 61 patients evaluable 61 OncoVEX GM CSF 61 lung resection 61 CIMZIA ™ 61 grade cervical intraepithelial 61 TKI therapy 61 FLT3 61 benign polyps 61 bevacizumab Avastin ® 61 mutated K ras 61 completely resected 61 ipsilateral breast 61 sentinel nodes 61 decitabine 61 DAPT 61 cisplatin chemotherapy 61 pituitary adenomas 61 sentinel node 61 ductal adenocarcinoma 61 thyroglobulin 61 hamartomas 61 cell carcinomas 61 carboplatin paclitaxel 61 dosing cohorts 61 refractory NSCLC 61 squamous cell 61 complete cytogenetic 61 BRAF mutations 61 orthotopic model 61 azacitidine 61 prostate epithelial cells 61 mycophenolate mofetil 61 colorectal cancers 61 relapsed ovarian cancer 61 #F FDG PET 61 T#I mutation 61 cervical lymph node 61 AQ4N 61 chlorambucil 61 refractory multiple myeloma 61 esophagogastric junction 61 sunitinib Sutent 61 glufosfamide 61 catheter angiography 61 non squamous 61 axillary node 61 F FDG PET 61 pertuzumab 61 histological subtype 60 cytoreductive nephrectomy 60 recanalization 60 oral ridaforolimus 60 meningiomas 60 transurethral resection 60 Proxinium TM 60 partial remissions 60 cell carcinoma 60 elacytarabine 60 mitomycin C 60 localized renal 60 follicular lymphoma 60 BRAF V#E mutation 60 MACCE 60 IV malignant melanoma 60 KRAS mutations 60 carcinoembryonic antigen CEA 60 endometrial carcinoma 60 carcinomas 60 huC# DM4 60 IDH1 mutation 60 alvespimycin 60 palliation 60 sunitinib 60 CR nPR 60 syngeneic 60 varices 60 reimplantation 60 gefitinib Iressa 60 activating mutations 60 genotypic resistance 60 premalignant 60 mutated KRAS 60 Azedra 60 adenomatous polyps 60 HER2 amplification 60 Metastatic 60 molecular subtypes 60 gemcitabine 60 T#I [002] 60 cediranib 60 ependymoma 60 glioblastomas 60 allogeneic bone marrow 60 metastatic GIST 60 colorectal carcinomas 60 papillary RCC 60 docetaxel chemotherapy 60 vinorelbine 60 MabCampath 60 endometrial hyperplasia 60 cytotoxic therapy 60 STRIDE PD 60 HCV infection 60 sorafenib 60 bone metastases 60 seminomas 60 metastatic malignant 60 alkylating agent 60 untreated metastatic melanoma 60 TNFa 60 nodal metastases 60 nutlin 3a 60 ascites 60 estrogen receptor ER 60 pre cancerous polyps 60 RAV# 60 radioiodine therapy 60 dasatinib 60 fluoropyrimidine 60 enzastaurin 60 Exherin TM 60 zalutumumab 60 colectomy 60 mediastinal 60 situ LCIS 60 severe neutropenia 60 mediastinal lymph nodes 60 5-FU/LV 60 renal carcinoma 60 AEG# 60 HER2 positive cancers 60 thrombotic complications 60 invasive carcinomas 60 prognostic biomarker 60 pegylated liposomal doxorubicin 60 tumors GIST 60 KRAS status 60 TAXUS Express Stent 60 recurrent prostate cancer 60 prostate cancer PCa 60 macroalbuminuria 60 HCV genotype 60 rFVIIa 60 EOquin TM 60 castrate resistant 60 indolent NHL 60 EpCAM 60 dosage regimens 60 postoperative radiotherapy 60 cintredekin besudotox 60 SUTENT 60 Sym# 60 grade gliomas 60 node metastases 60 huN# DM1 60 sentinel node biopsy 60 cholangiocarcinoma 60 evaluable subjects 60 leukemia ALL 60 clinically localized prostate 60 gastroesophageal junction 60 Gliadel Wafer 60 choroidal neovascularization 60 IFN beta 60 hematologic toxicity 60 pancreatic tumors 60 ASCT 60 liver transplant recipients 60 parathyroid 60 CA4P 60 neuroblastomas 60 epithelial ovarian cancer 60 radiochemotherapy 60 enucleation 60 metastatic colorectal cancer 60 epithelial ovarian 60 HSCT 60 RAS mutations 60 paclitaxel eluting stents 60 intravesical therapy 60 ELACYT 60 myeloproliferative diseases 60 Symadex 60 metastatic CRC 60 adenomas 60 metastatic lesion 60 Cotara 60 pelvic lymphadenectomy 60 EGFR TKI 60 cytotoxic chemotherapy 60 Irinotecan 60 fibrotic disease 60 chronic HCV 60 multicenter trials 60 virologic failure 60 cytogenetic response 60 pleural mesothelioma 60 standard chemotherapy regimen 60 allogeneic SCT 60 GRASPA ® 60 XELOX 60 vismodegib 60 gastrointestinal cancers 60 telomerase inhibition 60 T1c 60 FDG PET 60 tyrosine kinase inhibitors 60 EFAPROXYN 60 dacarbazine 60 docetaxel 60 systemically administered 60 gastric cancer 60 histologic subtype 60 uveal melanoma 60 gastric carcinoma 60 neoplasia 60 Lung transplantation 60 cutaneous melanoma 60 Kaplan Meier analysis 60 polycythemia vera PV 60 lymphoma CTCL 60 histopathologic examination 60 micafungin 60 EOquin 60 transitional cell carcinoma 60 LHRH receptor positive 60 FTY# 60 pancreatic tumor 60 trabectedin 60 plus dexamethasone 60 atypical hyperplasia 60 medulloblastomas 59 cisplatin vinorelbine 59 prostate cancers 59 imatinib 59 docetaxel Taxotere ® 59 metastasis 59 cisplatin resistant 59 retroperitoneal 59 fibrinolysis 59 BRAF inhibitor 59 leukemia CLL 59 cetuximab 59 thyroid nodules 59 partial nephrectomy 59 mutational status 59 preoperative radiotherapy 59 myeloproliferative disorders 59 lymph node metastasis 59 HER2 expression 59 CTAP# Capsules 59 myelofibrosis polycythemia vera 59 Xanafide 59 K#R [002] 59 malignant polyps 59 Torisel 59 lupus nephritis 59 pT3 59 G#DT 59 temsirolimus 59 total thyroidectomy 59 teriflunomide 59 liposomal doxorubicin 59 anterior uveitis 59 antitumor effect 59 adjuvant tamoxifen 59 autologous bone marrow 59 trastuzumab 59 timepoints 59 hepatic metastasis 59 EGFR receptor 59 nasopharyngeal carcinoma 59 benign lesions 59 androgen receptor AR 59 histological subtypes 59 histologic 59 fulvestrant 59 acute myelogenous leukemia AML 59 intravesical 59 PROSTVAC VF 59 CaP 59 Hematologic 59 radiotherapy RT 59 postoperative morbidity 59 KRAS mutant tumors 59 radical cystectomy 59 papillary 59 Hodgkin lymphoma HL 59 IRX 2 59 intra arterial 59 prostatic tissue 59 cerebral vasospasm 59 Thal Dex 59 carcinoma HCC 59 Mitomycin C 59 paclitaxel cisplatin 59 telaprevir dosed 59 Seliciclib 59 trastuzumab Herceptin ® 59 thromboembolic events 59 milatuzumab 59 sunitinib malate 59 TRUS biopsy 59 octreotide 59 mutated KRAS gene 59 palliative radiotherapy 59 metastatic lymph nodes 59 vidofludimus 59 prostate cancer HRPC 59 cisplatin 59 prostate tumor 59 neointimal 59 reintervention 59 prostate cancer mCRPC 59 systolic dysfunction 59 autologous SCT 59 GSTP1 59 node dissection 59 QuadraSphere 59 neovascularization 59 hyperoxaluria 59 chemotherapy cisplatin 59 choroidal neovascularization CNV 59 malignant ascites 59 free survival PFS 59 parathyroidectomy 59 anthracycline taxane 59 leiomyomas 59 external beam radiotherapy 59 SUVmax 59 multiple myeloma MM 59 Immunohistochemical analysis 59 glioma cells 59 immunocompetent 59 gastrectomy 59 sirolimus stent 59 neoplastic 59 variceal bleeding 59 arteriography 59 ancrod 59 squamous cell lung cancer 59 Allovectin 7 ® 59 pancreatic lung 59 contralateral breast cancer 59 rebleeding 59 activin 59 surgical resection 59 Alocrest 59 goserelin 59 esophagectomy 59 PKCi 59 ZACTIMA 59 tumor necrosis 59 YONDELIS 59 TTF Therapy 59 ependymomas 59 pulmonary metastasis 59 IGF IR 59 remission induction 59 octreotide LAR 59 HCV SPRINT 59 tamoxifen therapy 59 schwannomas 59 invasive aspergillosis 59 pilocytic astrocytomas 59 androgen suppression 59 mutated BRAF gene 59 rBChE 59 lymphomas 59 transplantation HCT 59 resection 59 FOLFOX 59 pathologic diagnosis 59 gemcitabine Gemzar 59 hormone receptor positive 59 anti angiogenic agents 59 lesions 59 extracranial 59 antiangiogenic therapy 59 sentinel lymph node 59 vitreous hemorrhage 59 Median survival 59 colorectal adenoma 59 TTR gene 59 Azixa 59 metastatic ovarian cancer 59 GRN# 59 recurrent malignant glioma 59 cutaneous squamous cell carcinoma 59 graft occlusion 59 malignant growths 59 JAK3 59 FOLFOX6 59 hormone refractory 59 candidemia 59 anti angiogenic therapy 59 IL 1ß 59 PEGylated interferon beta 1a 59 acute STEMI 59 NNRTI resistance 59 colorectal metastases 59 autologous transplants 59 recurrent ovarian 59 intraperitoneal therapy 59 Aflibercept 59 aromatase inhibitor therapy 59 everolimus eluting stents 59 definite stent thrombosis 59 Squamous 59 rindopepimut 59 subgroup analyzes 59 prostate tissue 59 therapeutic regimens 59 clodronate 59 mitomycin 59 refractory CLL 59 Fludara 59 kinase inhibition 59 MitraClip device 59 bladder tumors 59 lung nodules 59 B7 H3 59 Radical prostatectomy 59 PSA nadir 59 Ceflatonin 59 specific antigen PSA 59 repigmentation 59 vestibular schwannomas 59 subependymal giant cell 59 cangrelor 59 supratentorial 59 interferon alfa 59 AGTR1 59 tumor xenografts 59 medulloblastoma 59 cell lung cancer 59 Virulizin ® 59 metastatic renal cell 59 IL 1beta 59 SBRT 59 splenectomized patients 59 ALA PDT 59 advanced neoplasia 59 radiofrequency ablation RFA 59 luteinizing hormone releasing 59 bronchogenic carcinoma 58 leukaemias 58 lung carcinomas 58 alkaline phosphatase ALP 58 APTIVUS r 58 chemotherapy regimens 58 myelofibrosis MF 58 ixabepilone 58 Lymph node 58 saphenous vein grafts 58 hyperplasia 58 H. pylori eradication 58 TELCYTA 58 estramustine 58 timepoint 58 adjuvant therapies 58 malignant neoplasm 58 idiopathic myelofibrosis 58 gastrointestinal stromal tumor 58 bispecific antibody 58 radiation therapy SBRT 58 SCIg 58 lymphoid cells 58 topotecan 58 FOLFIRI 58 tumor biopsies 58 lumiliximab 58 HCV genotypes 58 AA amyloidosis 58 familial ALS 58 intrahepatic 58 ovarian cancers 58 EGFR TKIs 58 IV metastatic melanoma 58 chronic HBV infection 58 plus gemcitabine 58 myeloablative 58 sustained virological response 58 situ DCIS 58 darapladib 58 vWF 58 Leydig cell 58 L asparaginase 58 angiogenesis inhibitor 58 leukemic cells 58 ductal carcinomas 58 anti leukemic 58 bendamustine 58 myelofibrosis 58 immunosuppressive regimens 58 ALK mutations 58 prognostic indicator 58 vorinostat 58 acute leukemias 58 talactoferrin 58 EGFR mutation positive 58 BRCA mutation carriers 58 viral kinetics 58 contralateral 58 RNAi therapeutic targeting 58 precancers 58 malignancy 58 endocrine therapy 58 lymphadenopathy 58 surgical excision 58 amrubicin 58 thyroid carcinoma 58 Glioblastoma Multiforme 58 Renal Cell Carcinoma RCC 58 anaplastic 58 grade dysplasia 58 hA# 58 situ CIS 58 metastatic bone 58 durable remissions 58 vasospasm 58 virologic response 58 resistant hormone refractory 58 MYLOTARG 58 relapsing remitting 58 pain palliation 58 neoplastic lesions 58 prostate carcinomas 58 intracoronary 58 proximal colon 58 antiangiogenic 58 neointimal hyperplasia 58 HER2 receptor 58 CIN2 + 58 normal karyotype 58 CR# vcMMAE 58 IMA# 58 benign nodules 58 infarcts 58 chemo resistant 58 CINTREDEKIN BESUDOTOX 58 ductal breast cancer 58 fluorouracil 58 TroVax ® 58 HDACi 58 wedge resection 58 ischemic cardiomyopathy 58 XIENCE V PROMUS Stent 58 p# biomarker 58 axillary lymph node 58 HER2 positive breast cancer 58 pediatric malignancies 58 malignant transformation 58 CD# antibody [001] 58 endosonography 58 allogeneic HSCT 58 Trastuzumab 58 anthracycline chemotherapy 58 androgen independent 58 hTERT 58 tafamidis 58 ImmuKnow 58 T2DM 58 Glioma 58 BCG refractory 58 SHPT 58 hormone refractory prostate cancer 58 febrile neutropenia 58 ENMD # 58 relapsed MM 58 TIMP 58 autologous hematopoietic stem cell 58 HBeAg positive patients 58 idarubicin 58 renal transplantation 58 pre cancerous lesions 58 undetectable HBV DNA 58 pancreatectomy 58 colorectal neoplasms 58 VEGFR 58 lobular 58 non metastatic osteosarcoma 58 alveolar rhabdomyosarcoma 58 TIMP 1 58 HER-2/neu 58 Cholangiocarcinoma 58 colon tumors 58 invasive lobular carcinoma 58 PNH patients 58 haematopoietic 58 epithelioid 58 paricalcitol 58 c MYC 58 HGS ETR2 58 astrocytomas 58 adjuvant cisplatin 58 low dose cytarabine 58 esophageal carcinoma 58 CBLC# 58 paraganglioma 58 xenografts 58 refractory CTCL 58 erlotinib Tarceva 58 azacytidine 58 phase IIb trial 58 Enzastaurin 58 nab paclitaxel 58 idraparinux 58 pancreatic islet cell 58 Cytoxan 58 APOPTONE 58 lymphoid 58 hepatitis C genotype 58 virological response 58 etoposide 58 hepatic resection 58 oligodendroglioma 58 NAbs 58 FGFR2 58 haematological cancers 58 CTEPH 58 FDG uptake 58 DLBCL 58 IFN alpha 58 tumor regressions 58 keloid scarring 58 abiraterone acetate 58 NF kB pathway 58 talabostat 58 cranial radiation 58 nodal dissection 58 trans retinoic acid ATRA 58 xenograft tumors 58 geographic atrophy 58 surgically resectable 58 CLL SLL 58 advanced unresectable 58 EGF receptors 58 pediatric acute lymphoblastic 58 edifoligide 58 prophylactic cranial irradiation